{
    "code": 0,
    "data": [
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "The transcript of the Earnings Call held on Monday February 02 2026 has been uploaded on the Companys website.",
            "news_id": "559a2b2c-60a6-4c21-8343-aa5add4ce7da",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e557fd6c-8af4-4ae2-9928-68d5f083c904.pdf",
            "news_date": "2026-02-04 15:16:51",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Earnings Call Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "The transcript of the Earnings Call held on Monday February 02 2026 has been uploaded on the Companys website.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e557fd6c-8af4-4ae2-9928-68d5f083c904.pdf",
            "news_date": "2026-02-04 15:16:51"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Pursuant to the relevant provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform the details of Analyst / Institutional Investor meetings.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=36268720-11ad-4e5f-922a-068f6b742c06.pdf",
            "news_date": "2026-02-02 16:39:22"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby confirm that we have uploaded audio recording of Q3 FY 2025-26 Earnings Call held on 02nd February 2026 on the website of the Company.",
            "news_id": "801b3236-6fd1-4add-aefb-f783a58a5bbd",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dbc49df8-9d42-4521-b7be-1f74e8a53b1c.pdf",
            "news_date": "2026-02-02 13:38:05",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby confirm that we have uploaded audio recording of Q3 FY 2025-26 Earnings Call held on 02nd February 2026 on the website of the Company.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dbc49df8-9d42-4521-b7be-1f74e8a53b1c.pdf",
            "news_date": "2026-02-02 13:38:05"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "GENERAL",
            "caption": "Disclosure under Regulation 30A of LODR",
            "news_body": "Disclosure under Regulation 30 of the SEBI (LODR) Regulation 2015 - Regulatory Action/ Inspection",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2701b21c-1320-4c6e-a8ad-9c867a076c00.pdf",
            "news_date": "2026-01-31 21:16:49"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation - Q3 FY 25-26",
            "news_id": "219d4b86-a7fd-4d04-bdec-7669e0cec21c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=856749e4-3647-45da-8001-1814468ab0bc.pdf",
            "news_date": "2026-01-30 20:20:09",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation - Q3 FY 25-26",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=856749e4-3647-45da-8001-1814468ab0bc.pdf",
            "news_date": "2026-01-30 20:20:09"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Press Release and Management Discussion & Analysis of the Company for the Third Quarter ended December 31 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6be9c1f3-e472-4d69-95de-89084b700d6a.pdf",
            "news_date": "2026-01-30 20:12:40"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Unaudited Financial Results (Standalone And Consolidated) For The Third Quarter And Nine Months Ended 31St December 2025",
            "news_body": "Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform that the Board at its meeting held today has approved the unaudited financial results for the Third Quarter and Nine Months ended 31st December 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6704087e-e171-47f4-99af-8f163bd4c426.pdf",
            "news_date": "2026-01-30 20:07:14"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Enclosed please find herewith the details of Earnings Call slated for Monday February 02 2026 at 8:30 a.m. - 9:30 a.m. (IST) for your information and record. Please note that the recording of the call will be available on our website within 24 hours of the call.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dc488a90-e16d-430f-a760-ba72bf8393ea.pdf",
            "news_date": "2026-01-22 16:44:58"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "As per the Code of Conduct of Prevention of Insider Trading and pursuant to the provisions of the SEBI (PIT) Regulations 2015 the Company has intimated its Directors and Designated Persons regarding closure of trading window from December 31 2025 to February 1 2026 (both days inclusive) for the purpose of  approval of Unaudited Financial Results for the Third Quarter and Nine Months ended December 31 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ce4924c7-3b6b-49e5-a912-f0cbf890591e.pdf",
            "news_date": "2026-01-19 17:32:19"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Unaudited Financial Results Of The Company For The Third Quarter And Nine Months Ended December 31 2025.",
            "news_body": "Glenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2026 inter alia to consider and approve the Unaudited Financial Results of the Company for the Third Quarter and Nine Months ended December 31 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a8b73ccd-1cae-4812-89ad-9b4506ad86c9.pdf",
            "news_date": "2026-01-19 17:23:08"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Announcement Under Regulation 30 Of The SEBI (LODR)",
            "news_body": "Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (\"SEBI Listing Regulations\") - ESG Rating.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b38e1e96-513a-41ec-bc48-58bcf992c3bf.pdf",
            "news_date": "2026-01-05 16:43:40"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Glenmark Pharmaceuticals Inc. USA launches Epinephrine Injection USP 30 mg/ 30 mL (1 mg/mL) Multiple - Dose Vial",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=879d5be9-5170-40d1-9a73-383e330cf716.pdf",
            "news_date": "2025-12-23 08:44:39"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib an MHRA and NMPA approved Third - Generation EGFR-TKI from Hansoh Pharma",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d8133fd7-5afa-422f-883b-51a62688d9ea.pdf",
            "news_date": "2025-12-16 15:35:10"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Glenmark Pharmaceuticals Inc. USA to launch Leucovorin Calcium for Injection USP 350 mg/ vial Single - Dose Vial",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=80c4541a-f4f4-4e75-9b12-9cc5586498bf.pdf",
            "news_date": "2025-12-11 08:44:12"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Update On The Companys Chhatrapati Sambhajinagar (Aurangabad) Facility",
            "news_body": "Update on the Companys Chhatrapati Sambhajinagar (Aurangabad) Facility",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9c50bc49-126a-4376-b3f4-991a79cf11ca.pdf",
            "news_date": "2025-12-01 08:56:35"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Update On The Companys Monroe North Carolina (USA) Facility",
            "news_body": "Update on the Companys Monroe North Carolina (USA) Facility",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9a2c1f0d-c4fd-4168-8322-ef13f49ff86f.pdf",
            "news_date": "2025-11-27 10:15:48"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Glenmark Pharmaceuticals Announces Launch of Nebzmart GFB Smartules and Glenmark Airz FB Smartules Worlds First Nebulized Triple Therapy for COPD",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f766af87-64d4-40f2-8863-9c05386785a8.pdf",
            "news_date": "2025-11-25 09:00:58"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of Earnings Call is attached",
            "news_id": "02ed6cd0-aa10-4482-b3cd-8ca02d6cfdd7",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c995d72a-dd22-44a4-a163-01fcfee9a18e.pdf",
            "news_date": "2025-11-19 17:17:04",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Earnings Call Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of Earnings Call is attached",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c995d72a-dd22-44a4-a163-01fcfee9a18e.pdf",
            "news_date": "2025-11-19 17:17:04"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Cosmo and Glenmark Announce Market Authorization of Winlevi (clascoterone) 10mg/g cream for Treatment of Acne in 15 countries in Europe",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4562f445-a6b0-4bb6-9bf5-5f15346ff525.pdf",
            "news_date": "2025-11-18 14:40:40"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby confirm that we have uploaded audio recording of Q2 FY 2025-26 Earnings Call held on 17th November 2025 on the website of the Company",
            "news_id": "d07eaef4-a18e-4825-889a-274fc66bd732",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f588bf04-ebbe-402b-abcd-1b8e6aa897b4.pdf",
            "news_date": "2025-11-17 13:01:13",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby confirm that we have uploaded audio recording of Q2 FY 2025-26 Earnings Call held on 17th November 2025 on the website of the Company",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f588bf04-ebbe-402b-abcd-1b8e6aa897b4.pdf",
            "news_date": "2025-11-17 13:01:13"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Please find attached details of Analyst / Institutional Investor meeting.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=09248316-42c7-42df-bb32-87ae0f98c1e7.pdf",
            "news_date": "2025-11-14 18:19:04"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation - Q2 FY 25-26",
            "news_id": "bf943ffe-4845-464b-b214-d3f9a549bd84",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=56fa1426-7a72-499d-8b43-3b4d1fad129f.pdf",
            "news_date": "2025-11-14 18:12:17",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation - Q2 FY 25-26",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=56fa1426-7a72-499d-8b43-3b4d1fad129f.pdf",
            "news_date": "2025-11-14 18:12:17"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Please find attached Press Release and Management Discussion & Analysis for the second quarter ended September 30 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0c5229ee-c7d7-4467-ac6e-1604e7694619.pdf",
            "news_date": "2025-11-14 18:04:21"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Unaudited Financial Results (Standalone And Consolidated) For The Second Quarter And Half Year Ended 30Th September 2025",
            "news_body": "Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform that the Board at its meeting held today has approved the unaudited financial results for the Second Quarter and Half Year ended 30th September 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=368fe85e-0b50-4e97-a74d-4ae181819f4e.pdf",
            "news_date": "2025-11-14 17:51:43"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations 2015",
            "news_body": "Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f65a3af4-c295-4e96-a8ab-bdbb0a467c8b.pdf",
            "news_date": "2025-11-14 15:34:41"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Glenmark Secures China Approval for RYALTRIS Reinforcing Respiratory Innovation Leadership",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3d83c18d-3b2a-4d14-b9a4-e7a96a0c7b0e.pdf",
            "news_date": "2025-11-10 15:30:07"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Enclosed please find herewith the details of Earnings Call slated for Monday November 17 2025 at 8:30 a.m. - 9:30 a.m. (IST) for your information and record. Please note that the recording of the call will be available on our website within 24 hours of the call.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=abf47ec1-be36-4b8e-a712-b65f425b3dcc.pdf",
            "news_date": "2025-11-06 12:51:52"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Glenmark Pharmaceuticals Inc. USA launch 8.4% Sodium Bicarbonate Injection USP 50 mEq/ 50mL (1 mEq/ mL) Single - Dose Vial",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9759ab4e-ba6f-4e74-9292-497448a00453.pdf",
            "news_date": "2025-11-04 08:59:42"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "The Company has intimated regarding the closure of trading window from September 30 2025 to November 16 2025 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the second quarter and half year ended September 30 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e8c6f7aa-eef9-4ab9-969f-0f4d9526b71d.pdf",
            "news_date": "2025-11-03 17:38:20"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Second Quarter And Half Year Ended September 30 2025",
            "news_body": "Glenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 inter alia to consider and approve the Unaudited Financial Results of the Company for the second quarter and half year ended September 30 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=59b05364-a475-41e3-935a-ccc74a8836c0.pdf",
            "news_date": "2025-11-03 17:34:48"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Completion Of Transfer Of Companys Consumer Care Business",
            "news_body": "Completion of transfer of Companys Consumer Care business",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9600fd04-47b2-4994-8e13-2fe95f11ed3f.pdf",
            "news_date": "2025-11-01 12:04:48"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Glenmark Pharmaceuticals Inc. USA to launch Ropivacaine Hydrochloride Injection USP 40mg/20 mL (2 mg/mL) 150mg/30mL (5 mg/mL) and 200mg/20 mL (10 mg/mL) Single-Dose Vials",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f38a750c-85fb-458d-ab19-b19d767cb542.pdf",
            "news_date": "2025-10-23 09:15:51"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "Outcome",
            "descriptor": "AGM",
            "caption": "Shareholder Meeting / Postal Ballot-Scrutinizers Report",
            "news_body": "Report of Scrutinizer and Voting Result under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 is enclosed.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ac8c4015-a4df-472a-9ca8-0d7dd78f71ed.pdf",
            "news_date": "2025-09-26 19:09:46"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "Outcome",
            "descriptor": "AGM",
            "caption": "Shareholder Meeting / Postal Ballot-Outcome of AGM",
            "news_body": "Proceedings of the 47th AGM of the Company is enclosed.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=199c9caa-6437-47a2-bbdd-d32973ed7288.pdf",
            "news_date": "2025-09-26 19:02:35"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "Outcome",
            "descriptor": "Dividend",
            "caption": "Corporate Action-Board approves Dividend",
            "news_body": "Please refer enclosed file.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bca2e391-1125-449b-a2c6-8ef021527ded.pdf",
            "news_date": "2025-09-26 11:04:04"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On 26Th September 2025",
            "news_body": "The Board approved Interim Dividend of Rs. 2.50 per equity shares on face value of Re. 1/- per equity shares for the Financial Year 2025-26 and reconstitution of Committees.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cd038e67-ee28-4217-badd-599ad513ff8e.pdf",
            "news_date": "2025-09-26 10:48:35"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Glenmark Strengthens Oncology Portfolio with Hengruis HER2 Targeting ADC for Multiple Regions",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f89adb29-9456-4f77-bf1f-8f1d4aaf0ce0.pdf",
            "news_date": "2025-09-24 15:39:46"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "Intimation",
            "descriptor": "Book Closure",
            "caption": " Revision In Intimation Of Record Date For Interim Dividend",
            "news_body": "Revised record date for payment of interim dividend if declared will be Friday October 03 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3681ca01-e2ac-4fa5-9b76-d1f47feb9718.pdf",
            "news_date": "2025-09-22 17:40:33"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "Closure of Trading Window",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3e5677fa-d6a5-4bbe-bb3f-dd7dcab2fae2.pdf",
            "news_date": "2025-09-22 16:29:30"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "Intimation",
            "descriptor": "Record Date",
            "caption": "Intimation Of Record Date For Interim Dividend",
            "news_body": "Record date for payment of Interim Dividend if declared will be Tuesday September 30 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=80fe439d-71c5-4df0-b293-136bc14730c7.pdf",
            "news_date": "2025-09-22 16:11:33"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Considering And Approving Payment Of Interim Dividend",
            "news_body": "Glenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/09/2025 inter alia to consider and approve payment of interim dividend if any on Equity Shares of the Company for the financial year 2025-26.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c3c451fc-6ada-4b3b-9aaf-2f339100fb2f.pdf",
            "news_date": "2025-09-22 16:06:33"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Credit Rating",
            "caption": "Announcement under Regulation 30 (LODR)-Credit Rating",
            "news_body": "Kindly find enclosed rating rationale issued by CRISIL Ratings for your reference.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=065e8a69-e8db-4bc4-a8d4-94bc3122c2c1.pdf",
            "news_date": "2025-09-19 10:29:55"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Transfer Of The Companys Consumer Care Business",
            "news_body": "Further to the earlier intimation dated August 14 2025 we hereby advise that a Business Transfer Agreement for transfer of the Companys Consumer Care Business to Glenmark Consumer Care Limited a wholly owned subsidiary of the Company has been executed on September 15 2025. The transaction is expected to be completed on or before December 31 2025 subject to completion of customary conditions.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=53954cbf-ca3f-4f76-900b-c89af33837fa.pdf",
            "news_date": "2025-09-15 17:22:37"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Intimation Regarding Upfront Payment Received",
            "news_body": "Intimation regarding upfront payment received",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a5053dc9-a074-4247-8a67-2e5576ca778d.pdf",
            "news_date": "2025-09-09 08:53:08"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Please find attached details of Analyst / Institutional Investor Meet",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=edc4c1cc-41e3-4536-9924-1b46a495a286.pdf",
            "news_date": "2025-09-08 20:11:25"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Glenmark initiates a Multi-Country Phase 3 Clinical Trial for Envafolimab in Resectable Stage III Non-Small Cell Lung Cancer",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f1b827be-f8f6-48c3-b2c1-842447832b15.pdf",
            "news_date": "2025-09-05 09:48:13"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Glenmark Pharmaceuticals Inc. USA to launch Eribulin Mesylate Injection 1mg/2Ml (0.5 mg/mL) Single-Dose Vials",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4f6323a4-cf90-452e-893c-e441c523a7d8.pdf",
            "news_date": "2025-09-02 10:27:52"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Please find enclosed copy of newspaper advertisement published in Financial Express (English) and Loksatta (Marathi)",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=224f074d-78f3-4c85-81e2-d69da0c8354b.pdf",
            "news_date": "2025-09-01 17:58:19"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Please find enclosed Newspaper Publications regarding opening of special window for re-lodgement of transfer requests of physical shares.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cb60c056-93f4-4e68-9843-be20ae2deb84.pdf",
            "news_date": "2025-09-01 17:49:23"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "Intimation",
            "descriptor": "Record Date",
            "caption": "Intimation Of Record Date For Dividend",
            "news_body": "Intimation of Record Date For Dividend",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e305a921-47b3-49bb-8da3-269aa55f4959.pdf",
            "news_date": "2025-08-29 19:34:35"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Business Responsibility and Sustainability Reporting (BRSR)",
            "caption": "Business Responsibility and Sustainability Reporting (BRSR)",
            "news_body": "Please find attached Business Responsibility and Sustainability Report (BRSR) of the Company for FY 2024-25.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9a3b7d1f-6dd2-4c69-b12f-63e42c535acd.pdf",
            "news_date": "2025-08-29 19:30:27"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Reg. 34 (1) Annual Report",
            "caption": "Reg. 34 (1) Annual Report.",
            "news_body": "Pursuant to Regulation 34(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find attached the Integrated Annual Report for the Financial Year\r\n2024-25.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d3b75907-c1d1-4607-a8d1-7b01cf5078af.pdf",
            "news_date": "2025-08-29 19:08:35"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "Intimation",
            "descriptor": "AGM",
            "caption": "Notice Of 47Th Annual General Meeting Of The Company For F.Y. 2024-25 As Required Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015",
            "news_body": "Notice and Explanatory Statement convening the 47th Annual General Meeting scheduled to be held on Friday September 26 2025 at 02:00 p.m. IST through VC / OAVM is enclosed.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c382d41c-3fb3-40d3-8b5b-1182add9207e.pdf",
            "news_date": "2025-08-29 18:51:41"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Transcript of the Earnings Call is attached.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9a22c737-4e25-4b9c-a163-b5ee36dbc2c3.pdf",
            "news_date": "2025-08-28 20:17:57"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Please find attached details of Analyst / Institutional Investor Meetings",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ee57be3f-7739-4032-ac01-6f05eeef221f.pdf",
            "news_date": "2025-08-28 19:46:21"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Intimation Of Book Closure Pursuant To Regulation 42 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015",
            "news_body": "Register of Members and the Share Transfer Books of the Company will remain close from Tuesday September 16 2025 to Friday September 26 2025 (both days inclusive) for the purpose of the 47th Annual General Meeting scheduled to be held on Friday September 26 2025 and also for determining the names of the shareholders to whom the dividend which if declared at the Annual General Meeting will be payable.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=852f465d-ff2c-4e67-bae0-babd04863787.pdf",
            "news_date": "2025-08-22 17:56:50"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Update On Acquisition Of Securities Of O2 Renewable Energy XXIV Private Limited",
            "news_body": "Update on acquisition of securities of O2 Renewable Energy XXIV Private Limited",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1fb55ed7-b14b-4c2b-a9d7-657affbfea4b.pdf",
            "news_date": "2025-08-20 18:30:24"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Glenmark Pharmaceuticals Inc. USA to launch Micafungin for Injection USP 50 mg/vial and 100 mg/vial (Single-Dose vial)",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c2fc6b41-bc6c-4d5c-9b1b-473b3bc03c2c.pdf",
            "news_date": "2025-08-19 09:51:53"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Please find attached herewith details of Analyst / Institutional Investor Meeting.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3ed7369e-7601-4539-bb88-975780011bd5.pdf",
            "news_date": "2025-08-14 18:59:16"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation - Q1 FY 25-26",
            "news_id": "e8e3b00b-9029-440f-8675-7b4cbc19d03b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d6139070-f93f-4e0b-b520-cdcf5431009a.pdf",
            "news_date": "2025-08-14 18:21:34",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation - Q1 FY 25-26",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d6139070-f93f-4e0b-b520-cdcf5431009a.pdf",
            "news_date": "2025-08-14 18:21:34"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Transfer Of The Companys Consumer Care Business To Its Newly Incorporated Wholly Owned Subsidiary Glenmark Consumer Care Limited",
            "news_body": "Approved the transfer of the Companys Consumer Care business to its newly incorporated wholly owned subsidiary Glenmark Consumer Care Limited.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d25134e6-e7d3-4486-a426-8e249ebdce76.pdf",
            "news_date": "2025-08-14 18:13:19"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Appointment Of Secretarial Auditor",
            "news_body": "Approved the appointment of M/s. Rauthan & Associates LLP as the Secretarial Auditors of the Company",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=712292ca-9c4a-446e-9b10-669622006db8.pdf",
            "news_date": "2025-08-14 18:06:00"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Appointment of Statutory Auditor/s",
            "caption": "Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s",
            "news_body": "Approved the appointment of M/s. Walker Chandiok & Co. LLP as the Statutory Auditors of the Company",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0b32e66d-6548-4d1d-9885-141b01cbfc64.pdf",
            "news_date": "2025-08-14 18:02:42"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Change in Directorate",
            "caption": "Announcement under Regulation 30 (LODR)-Change in Directorate",
            "news_body": "Appointment of Ms. Patricia Andrews as an Additional Director (Non-Executive Independent Director) of the Company.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7590cf82-2d05-41ee-b8bc-c169f1200fbd.pdf",
            "news_date": "2025-08-14 17:59:02"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On 14Th August 2025",
            "news_body": "Outcome of the Board Meeting held on 14th August 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=db9d1c7d-b06f-49ca-a662-e9b683957a4a.pdf",
            "news_date": "2025-08-14 17:55:14"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Please find attached Press Release and Management Discussion & Analysis of the Company for the first quarter ended June 30 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fd0c8881-4c3c-4d3c-a1ed-a566560a0391.pdf",
            "news_date": "2025-08-14 17:41:03"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) For The First Quarter Ended 30Th June 2025",
            "news_body": "Please find attached herewith Unaudited Financial Results for the first quarter ended 30th June 2025",
            "news_id": "477f84e9-7149-4cf0-b8ec-621db6f016d7",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b72a6b85-71e4-4be2-a5d3-39c2effe26cd.pdf",
            "news_date": "2025-08-14 17:14:39",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "Outcome",
            "descriptor": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) For The First Quarter Ended 30Th June 2025",
            "news_body": "Please find attached herewith Unaudited Financial Results for the first quarter ended 30th June 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b72a6b85-71e4-4be2-a5d3-39c2effe26cd.pdf",
            "news_date": "2025-08-14 17:14:39"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Enclosed please find herewith the details of Earnings Call slated for Monday August 18 2025 at 8:30 a.m. - 9:30 a.m. (IST) for your information and record.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a935cb2c-4cdc-4615-bc65-d335566160ad.pdf",
            "news_date": "2025-08-08 16:15:11"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015",
            "news_body": "Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=64545c3d-44c5-44bf-9535-5ba468730e18.pdf",
            "news_date": "2025-08-06 20:33:56"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "The trading window has been closed from June 30 2025 to August 16 2025 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the First Quarter ended June 30 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=02980137-fa9a-47e9-81e0-6166ecdc6634.pdf",
            "news_date": "2025-08-04 17:43:41"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Considering And Approving The Financial Results For The First Quarter Ended June 30 2025",
            "news_body": "Glenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2025 inter alia to consider and approve the Unaudited Financial Results of the Company for the First Quarter ended June 30 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=54e7c40e-5ab7-4cbb-bc8f-0fa121b0348a.pdf",
            "news_date": "2025-08-04 17:33:58"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "Outcome",
            "descriptor": "Postal Ballot",
            "caption": "Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot",
            "news_body": "Voting result as required under Regulation 44(3) of SEBI Listing Regulations and Scrutinizers Report is enclosed.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7ad11cef-9a9c-4b09-847d-efc7cf428756.pdf",
            "news_date": "2025-08-01 19:19:18"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Newspaper Advertisement for transfer of Equity Shares to IEPF Authority.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=932631c3-c9f2-4c38-854b-6e7bf43c53f7.pdf",
            "news_date": "2025-07-25 14:57:42"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Credit Rating",
            "caption": "Announcement under Regulation 30 (LODR)-Credit Rating",
            "news_body": "Kindly find enclosed rating rationale issued by India Ratings and Research for your reference.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9a75095c-c5dc-42f2-a317-34bb09a4e385.pdf",
            "news_date": "2025-07-23 16:40:03"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "General",
            "cat": "Audio",
            "caption": "Audio Recording Of The Glenmark Pharmaceuticals Limited - Investor Day 2025",
            "news_body": "Audio recording of Investor Day 2025 held on 16th July 2025.",
            "news_id": "562de002-e0be-45e5-bf79-952d13159b70",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=740ed0cc-a602-497e-975f-1c66c12d2b1b.pdf",
            "news_date": "2025-07-23 16:11:42",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Audio Recording Of The Glenmark Pharmaceuticals Limited - Investor Day 2025",
            "news_body": "Audio recording of Investor Day 2025 held on 16th July 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=740ed0cc-a602-497e-975f-1c66c12d2b1b.pdf",
            "news_date": "2025-07-23 16:11:42"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Day 2025 Presentation is enclosed for reference.",
            "news_id": "275e5357-cadf-446b-8cbd-fc153c3e37d8",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5659eafc-f281-4f83-bbde-3c181a311e99.pdf",
            "news_date": "2025-07-16 16:31:20",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Day 2025 Presentation is enclosed for reference.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5659eafc-f281-4f83-bbde-3c181a311e99.pdf",
            "news_date": "2025-07-16 16:31:20"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015",
            "news_body": "Communication from U.S. FDA",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=896416d5-6150-4a59-9ac2-7560d33e6275.pdf",
            "news_date": "2025-07-12 21:29:33"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "We hereby notify the schedule of Analyst / Institutional Investors Meeting.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6da284c8-2aca-462e-ae09-2f9b8018e802.pdf",
            "news_date": "2025-07-10 18:09:03"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Ichnos Glenmark Innovation (IGI) Announces Global Commercialization Strategy for ISB 2001 Following Licensing Deal with AbbVie",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e11a1f2a-f96f-468d-9b30-e6449dee9ee2.pdf",
            "news_date": "2025-07-10 16:58:39"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001 a First-in-Class CD38xBCMAxCD3 Trispecific Antibody",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=793b4cde-a6dd-4f17-a6a0-d9d6ab2cff85.pdf",
            "news_date": "2025-07-10 16:53:20"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Newspaper Advertisement of Postal Ballot Notice",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4b75755e-221a-42d9-8f01-268359f17081.pdf",
            "news_date": "2025-07-02 13:34:07"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Intimation Under Regulation 30 (5) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015",
            "news_body": "Pursuant to Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 details of Key Managerial Personnel of the Company who are severally authorised for determining materiality of an event or information and for the purpose of making disclosures to stock exchanges is attached.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1890d88f-ae2e-41f8-b6cd-6915556e29bd.pdf",
            "news_date": "2025-07-01 16:21:22"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "Intimation",
            "descriptor": "Postal Ballot",
            "caption": "Shareholder Meeting / Postal Ballot-Notice of Postal Ballot",
            "news_body": "Intimation regarding Postal Ballot Notice",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cf2216eb-e0b5-4cbf-9207-6bad26af1d40.pdf",
            "news_date": "2025-07-01 15:57:07"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Glenmark Pharmaceuticals Launches TEVIMBRA in India: Expanding Access to Innovative Immuno-Oncology Treatment for Non-Small Cell Lung Cancer and Esophageal Squamous Cell Carcinoma",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=eb903d64-89aa-45ad-b359-43496d323533.pdf",
            "news_date": "2025-06-24 09:48:11"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Cessation",
            "caption": "Announcement under Regulation 30 (LODR)-Cessation",
            "news_body": "Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0e684b6c-1ab1-4985-a027-3243d64b1339.pdf",
            "news_date": "2025-06-20 17:11:54"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011",
            "news_body": "The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for HDFC Mutual Fund",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=521273C6_1ECD_482B_8E7C_CDC41A23688F_083737.pdf",
            "news_date": "2025-06-19 08:37:45"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "U.S. FDA Inspection At The Companys Facility At Monroe North Carolina USA",
            "news_body": "U.S. FDA inspection at the Companys facility at Monroe North Carolina USA",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0aa94874-6f08-45ad-8c3a-db4703d35196.pdf",
            "news_date": "2025-06-18 08:59:50"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Glenmark Pharmaceuticals to launch DCGI - approved BRUKINSA in India to Advance Treatment of Hematological Malignancies",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b59347c4-c670-48c1-aa0a-633966aa397f.pdf",
            "news_date": "2025-06-09 10:32:31"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Full Dose - Esclation Data Show Continued High Response Rates and Favourable Safety Profile of ISB  2001 a First-in-Class BCMA x CD38 x CD3 Trispecific Antibody for the Treatment of Relapsed/ Refractory Multiple Myeloma",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e50eacec-47af-4d27-9998-34d84b86035d.pdf",
            "news_date": "2025-06-02 18:37:05"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Further to our letter dated 19th May 2025 and pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (LODR) Regulations 2015 the transcript of the Earnings call held on Monday May 26 2025 for the fourth quarter ended March 31 2025 has been uploaded on the Companys website.",
            "news_id": "6f13ccef-def5-40a5-8dc2-e445cf8dc5ad",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b8d7f8ed-6f40-476a-914a-2b00435fa31a.pdf",
            "news_date": "2025-05-27 18:12:59",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Earnings Call Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Further to our letter dated 19th May 2025 and pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (LODR) Regulations 2015 the transcript of the Earnings call held on Monday May 26 2025 for the fourth quarter ended March 31 2025 has been uploaded on the Companys website.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b8d7f8ed-6f40-476a-914a-2b00435fa31a.pdf",
            "news_date": "2025-05-27 18:12:59"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "Compliance",
            "descriptor": "Reg.24(A)-Annual Secretarial Compliance",
            "caption": "Compliances-Reg.24(A)-Annual Secretarial Compliance",
            "news_body": "Attaching herewith the Annual Secretarial Compliance Report for the Financial Year 2024-25.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3d57b327-4125-4b65-94b2-6e443e3d13c4.pdf",
            "news_date": "2025-05-26 18:02:22"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby confirm that we have uploaded audio recording of Q4 FY 2024-25 earnings call held on 26th May 2025 on the website of the Company.",
            "news_id": "71900f70-ac43-4760-8458-813ad1a6f5be",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ebf8a7bf-f74a-428a-a36d-85b0be147fff.pdf",
            "news_date": "2025-05-26 17:46:50",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby confirm that we have uploaded audio recording of Q4 FY 2024-25 earnings call held on 26th May 2025 on the website of the Company.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ebf8a7bf-f74a-428a-a36d-85b0be147fff.pdf",
            "news_date": "2025-05-26 17:46:50"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Intimation Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) By Glenmark Pharmaceuticals Limited (GPL) In Respect Of Incorporation Of A Wholly Owned ",
            "news_body": "We wish to inform you that a wholly owned subsidiary company of GPL in the name of \"Glenmark Consumer Care Limited\" has been incorporated on May 23 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=72721d94-c4c1-4131-8166-3f323af82875.pdf",
            "news_date": "2025-05-23 22:33:07"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation Q4 F.Y. 2024-25",
            "news_id": "0649b3f6-58b6-4cf1-a04c-21c5a3096734",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4caf64a2-3797-4495-8cea-68f00d80fc01.pdf",
            "news_date": "2025-05-23 21:24:01",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation Q4 F.Y. 2024-25",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4caf64a2-3797-4495-8cea-68f00d80fc01.pdf",
            "news_date": "2025-05-23 21:24:01"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Please find enclosed herewith Press Release and Management Discussion & Analysis for the Fourth Quarter and year ended March 31 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4bb99701-cd6e-4249-a19a-5ac718d56d8c.pdf",
            "news_date": "2025-05-23 20:10:16"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "Intimation",
            "descriptor": "Dividend",
            "caption": "Corporate Action-Board to consider Dividend",
            "news_body": "The Board has recommended dividend of Rs. 2.5/- per share (face value of Re. 1/- each) on the equity shares capital of the Company for the financial year 2024-25 subject to the approval of the Shareholders at the ensuing Annual General Meeting.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ef76849f-cc38-4919-bf6b-493406a7f041.pdf",
            "news_date": "2025-05-23 19:51:59"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Change in Directorate",
            "caption": "Announcement under Regulation 30 (LODR)-Change in Directorate",
            "news_body": "Appointment of Mr. Anurag Mantri as an Additional Director (Whole-Time Director - Designated as Executive Director) and Global Chief Financial Officer of the Company",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=26bda5f5-8813-4d62-9667-34d71c196708.pdf",
            "news_date": "2025-05-23 19:46:47"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Audited Financial Results And Recommendation Of Final Dividend",
            "news_body": "The Board of Directors of Glenmark Pharmaceuticals Limited at its meeting held on 23rd May 2025 which commenced at 02.00 p.m. and concluded at 04:54 p.m. considered and approved the following:\r\n\r\n1. Audited Financial Results for the quarter and year ended March 31 2025. Pursuant to regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 find enclosed herewith the said results together with Auditors Report and Declaration of unmodified opinion. These are also being made available on the website of the Company at www.glenmarkpharma.com.\r\n\r\n2. Recommended Dividend @ 250% i.e. Rs. 2.5/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2024-25 subject to the approval of the Shareholders at the ensuing Annual General Meeting.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=348993b4-1152-4352-97ff-80607fb70b65.pdf",
            "news_date": "2025-05-23 19:39:20"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Intimation Of Grant Of Options Under Glenmark Pharmaceuticals Limited Employee Stock Option Scheme 2016",
            "news_body": "Approval for grant of 119318 options pursuant to \"Glenmark Pharmaceuticals Limited Employee Stock options Scheme 2016.\"",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cbbf5b90-b2e5-4efc-9b5d-32c8bdca7411.pdf",
            "news_date": "2025-05-22 14:19:09"
        },
        {
            "co_code": 20600,
            "bse_code": 532296,
            "isin": "INE935A01035",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Enclosed please find herewith the details of Earnings Call slated for Monday May 26 2025 at 8:30 a.m. - 9:30 a.m. (IST) for your information and record. Please note that the recording of the call will be available on our website within 24 hours of the call.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=987adedb-d04a-4b91-86fb-4cd8c959a49c.pdf",
            "news_date": "2025-05-19 10:29:12"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Further to our letter dated 5th February 2025 and pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (LODR) Regulations 2015 the transcript of the Earnings Call held on Monday 17th February 2025 for the third quarter ended December 31 2024 has been uploaded on the Companys website.",
            "news_id": "d16236a5-d30b-4d01-9571-8135d127cb8f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7b9efbda-ee4a-4042-91ea-1698580069eb.pdf",
            "news_date": "2025-02-19 17:01:37",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation - Q3 FY 24-25",
            "news_id": "66654668-262f-4b59-bee8-009031a569ca",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6dc274d1-2f3b-4867-afd7-26f68eed8911.pdf",
            "news_date": "2025-02-14 19:04:02",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of earnings call held on Monday, November 18, 2024 for the second quarter ended September 30, 2024 has been uploaded on Company''s website.",
            "news_id": "082b2214-c50c-45b3-b6fd-47a1f1414954",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7a5cc6e3-bbc1-473a-9506-b5999588c822.pdf",
            "news_date": "2024-11-21 17:19:47",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby confirm that we have uploaded audio recording of Q2 FY 2024 - 25 Earnings Call held on 18th November, 2024 on the website of the Company.",
            "news_id": "8eb1c80c-e75b-4cdc-91b0-2182b6e9966b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a696c3d7-be75-40a1-a8d5-a8131b4753e4.pdf",
            "news_date": "2024-11-18 15:57:24",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation - Q2 FY 24-25",
            "news_id": "0aff3895-f0f5-4f1e-b916-5e58386e1bb3",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=85d2b081-3caf-4aef-b2dc-8d3e51336c19.pdf",
            "news_date": "2024-11-14 19:47:46",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of earnings call held on Friday, August 16, 2024 for the first quarter ended June 30, 2024 has been uploaded on Company''s website.",
            "news_id": "ba95694c-61eb-4667-aebd-b0a495917185",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e07f0ee2-79b8-419c-be62-6a5911f989ca.pdf",
            "news_date": "2024-08-20 15:39:39",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio Recording for Q1 FY 2024-25 has been uploaded on Company''s website.",
            "news_id": "70d6c7c6-0474-49ec-bae2-ee6977452f67",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ac617c07-2608-473b-8fac-6da9dfd020f3.pdf",
            "news_date": "2024-08-16 11:54:42",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation - Q1 FY 24-25 attached.",
            "news_id": "856990b4-f5e3-44ee-953d-e55e1a3ee56b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b20d8d1f-1613-4f19-b8ce-8445e569d054.pdf",
            "news_date": "2024-08-14 18:50:56",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "General",
            "cat": "Audio",
            "caption": "Audio Recording Of The Glenmark Pharmaceuticals Limited - Investor Day 2024",
            "news_body": "Audio Recording of Investor Day 2024 held on 30th May, 2024",
            "news_id": "185814cf-0398-482e-a877-d41aec01dee8",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=263b21b1-5361-4d4a-b408-436169f88361.pdf",
            "news_date": "2024-05-31 08:42:33",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Further to our communication dated 17th May, 2024, attached is the copy of the presentation to be made at Glenmark Pharmaceuticals Limited Investor Day 2024 which is scheduled today in Mumbai.",
            "news_id": "7eece272-5daa-42c7-a9ca-4cb1df175863",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0f91f708-893b-4a3d-a8cf-ac4f2b99995a.pdf",
            "news_date": "2024-05-30 17:06:11",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "The transcript of the Earnings Call held on May 27, 2024 has been uploaded on the Company''s website.",
            "news_id": "f4a22628-bf69-42a8-a873-9e36fa9e84c5",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=12c38fea-32b1-4125-a8d1-a580478385fe.pdf",
            "news_date": "2024-05-29 18:00:45",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby confirm that we have uploaded audio recording of Q4 2023-24 Earnings call held on 27th May 2024, on the website of the Company",
            "news_id": "7c82434e-81c5-474c-9dce-cb4ffa92a6a3",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7f283cf7-82fe-4d69-885e-87210a76a5b2.pdf",
            "news_date": "2024-05-27 16:20:15",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation Q4 FY 23-24 and FY 23-24.",
            "news_id": "a51f15fc-9811-4384-895d-d641b9073a52",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9fa7d259-23f1-478c-85bd-7eb246f1b35f.pdf",
            "news_date": "2024-05-24 23:26:40",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "The transcript of the Earnings Call held on Friday, February 16, 2024 for the third quarter and nine months ended December 31, 2023 has been uploaded on the Company''s website.",
            "news_id": "5605e193-fdd1-455e-95de-c3b8786db99c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8af58f75-5319-4b22-ba23-4d25e7365312.pdf",
            "news_date": "2024-02-19 10:56:16",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby confirm that we have uploaded audio recording of Q3 FY 2023-24 Earnings Call held on 16th February, 2024 on the website of the Company.",
            "news_id": "64ce99ac-bedd-4d34-a812-0143e749836d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ea6ff388-ab16-4175-86ed-e1cf9abfbbd7.pdf",
            "news_date": "2024-02-16 12:58:15",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation Q3 FY23-24",
            "news_id": "547f2da5-99a8-44ac-8302-d67d4e4e4465",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1754436d-4da9-4ee0-9a44-b4dde158c324.pdf",
            "news_date": "2024-02-14 20:03:17",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Unaudited Financial Results (Standalone And Consolidated) For The Third Quarter And Nine Months Ended December 31, 2023",
            "news_body": "Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting, approved the Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2023.<BR> <BR> The said meeting of the Board commenced at 2.00 p.m. and concluded at 06:20 p.m.<BR> <BR> The copy of the said results and Limited Review Report of Auditors is enclosed herewith.<BR>  <BR> These are also being made available on the website of the Company",
            "news_id": "8c0896c1-1db3-48ef-a204-2b348849f381",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9664d8f2-05c6-4fb7-983f-1683b177590b.pdf",
            "news_date": "2024-02-14 18:44:51",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "The transcript of the Earnings Call held on Wednesday, November 15, 2023 for the second quarter and half year ended September 30, 2023 has been uploaded on the Company''s website.",
            "news_id": "59f15b1e-d31c-4a54-a654-25d28a6353bc",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4ecd601e-4c1b-4b7d-a41a-bbf745608866.pdf",
            "news_date": "2023-11-20 16:18:05",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby confirm that we have uploaded audio recording of Q2 FY 2023-24 Earnings Call held on 15th November, 2023 on the website of the Company.",
            "news_id": "da2dfbee-6286-4301-ace4-d7de25dcdaf6",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f2b87942-95ad-4490-b101-4a250eb92610.pdf",
            "news_date": "2023-11-15 17:39:25",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation Q2 FY 23-24",
            "news_id": "44f9f578-60fd-4337-9808-a8a9abff557b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=475259ee-4bb0-453d-85ec-ed5402ee048e.pdf",
            "news_date": "2023-11-10 21:11:40",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Unaudited Financial Results (Standalone And Consolidated) For The Second Quarter And Half Year Ended 30Th September, 2023",
            "news_body": "Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board at its meeting held today has approved the unaudited financial results for the Second Quarter and Half Year ended 30th September, 2023. The said Board Meeting commenced at 02:00 p.m. and ended at 06:40 p.m. The copy of the said results and Limited Review Report of Auditors is enclosed herewith. These are also being made available on the website of the Company at www.glenmarkpharma.com.",
            "news_id": "2692324e-d369-499e-98f2-8334f8198794",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cd21a91c-2316-4e78-9509-cf52e9c498de.pdf",
            "news_date": "2023-11-10 18:57:41",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation - Glenmark Pharma announces proposed divestment of Majority Stake in Glenmark Life Sciences Limited",
            "news_id": "efdaea3e-9855-4810-814b-1baf4b61acc1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c8382289-c246-4331-9ebf-53a00bbf84e6.pdf",
            "news_date": "2023-09-21 18:50:42",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "The transcript of the Earnings Call held on Monday, August 14, 2023 for the first quarter ended June 30, 2023 has been uploaded on the Company''s website.",
            "news_id": "145fde97-6d9c-4909-a879-7dbaa350fb6a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=61f9a8c2-a531-4146-830f-3c03f60d3050.pdf",
            "news_date": "2023-08-21 16:59:50",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby confirm that we have uploaded audio recording of Q1 FY 2023-24 Earnings Call held on 14th August, 2023 on the website of the Company.",
            "news_id": "da496389-803a-4e0a-9948-102ecfad1e6b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=70c1fef9-f953-41ce-a0d0-3cc01dee6ee1.pdf",
            "news_date": "2023-08-14 17:01:58",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation - Q1 FY 23-24",
            "news_id": "7077160d-a922-48ad-add8-bac8eeacbb97",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ae9f84c7-0698-4673-b390-7bd81e4cfd7e.pdf",
            "news_date": "2023-08-11 18:45:38",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) For The First Quarter Ended  30Th June, 2023",
            "news_body": "Unaudited Financial Results (Standalone and Consolidated) for the First Quarter ended 30th June, 2023",
            "news_id": "19daaf55-1105-47c2-9646-aa11cf87b567",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=33e95a36-ca7c-4bcd-b529-08fc784b39ac.pdf",
            "news_date": "2023-08-11 18:01:38",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the Earnings Call",
            "news_id": "f6b0983c-d5b0-4e83-b2ed-5c6e6a8b6afd",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e4199010-413e-4507-b52e-68304100feed.pdf",
            "news_date": "2023-05-25 11:42:54",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby confirm that we have uploaded audio recording of Q4 of FY 2022-23 Earnings Call held on 22nd May, 2023 on the website of the Company.",
            "news_id": "4b7f195b-64b9-4dd2-9cd2-0b36be57f96b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=583ccc99-674e-4eed-862b-e7f3ffd35495.pdf",
            "news_date": "2023-05-22 15:08:34",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the investor presentation - Q4 FY 22-23 & FY 22-23.",
            "news_id": "e8f3f4ba-7a40-4b05-b137-45b82ec88c09",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=64d89a7f-11cc-401a-99d3-52141d884373.pdf",
            "news_date": "2023-05-19 20:36:53",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results For The Quarter And Year Ended March 31, 2023",
            "news_body": "The Board of Directors of Glenmark Pharmaceuticals Limited at its meeting held on May 19, 2023, which commenced at 02.00 p.m. and concluded at 06.40 p.m., considered and approved the following:<BR> <BR> 1. Audited Financial Results for the quarter and year ended March 31, 2023. Pursuant to regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, find enclosed herewith the said results together with Auditors Report and Declaration of unmodified opinion. These are also being made available on the website of the Company at www.glenmarkpharma.com <BR> <BR> 2. Recommended Dividend @ 250% i.e. Rs. 2.50/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2022-23 subject to the approval of the Shareholders at the ensuing Annual General Meeting.",
            "news_id": "4cccc6ff-5e4e-40b1-939a-8fba054a5990",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c395378e-d7d1-4206-9d4d-1318793dd88b.pdf",
            "news_date": "2023-05-19 19:00:00",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the Earnings Call",
            "news_id": "b8fc7268-d35b-4639-896b-502a770b6c9c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d9a0f290-cf94-4692-8a1d-400da3e05b74.pdf",
            "news_date": "2023-02-15 17:54:46",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby confirm that we have uploaded audio recording of Q3 of FY 2022-23 Earnings Call held on 13th February, 2023 on the website of the Company.",
            "news_id": "acb0466e-733e-46a1-81bf-b8287c750b65",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0f6b7ec4-d890-4964-ae15-42b5d6062add.pdf",
            "news_date": "2023-02-13 13:06:44",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the Investor Presentation Q3 FY23.",
            "news_id": "019c4fbd-cf69-4ae6-b997-0fb7e0f2cc59",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ad7ff6c6-8655-4dc4-a261-c53a6314cf51.pdf",
            "news_date": "2023-02-10 20:14:08",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) For The Third Quarter And Nine Months Ended December 31, 2022",
            "news_body": "Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting, approved the Unaudited Financial Results for the<BR> Third Quarter and Nine Months ended December 31, 2022.<BR> The said meeting of the Board commenced at 2.00 p.m. and concluded at 7.25 p.m.<BR> The copy of the said results together with Management Discussion & Analysis, Press Release and Limited Review Report of the Auditors is enclosed herewith.<BR> These are also being made available on the website of the Company.",
            "news_id": "99181423-3b2e-4eab-913e-7551c045cd45",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=66e798c3-956e-4c7f-9b1a-86d560dcc215.pdf",
            "news_date": "2023-02-10 19:47:01",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transactions For The Half Year Ended 30Th September, 2022",
            "news_body": "Disclosure of Related Party Transactions for the half year ended 30th September, 2022",
            "news_id": "fa5a9edc-6304-472b-85e6-ff8db8b74dc6",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bd0ea7d2-6298-4c5e-833c-aba49c3c9e39.pdf",
            "news_date": "2022-11-25 21:52:56",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Further to our letter dated 03rd November, 2022 and pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (LODR), Regulations 2015, the transcript of the Earnings call held on Monday, November 14, 2022 for the quarter and half year ended September 30, 2022 has been uploaded on the Company's website",
            "news_id": "26dea815-9e75-4a1b-89ec-7ff596493fdb",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=65080f5c-eedf-49ea-8e85-86fce45d513d.pdf",
            "news_date": "2022-11-18 16:17:11",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Further to our communication dated November 11, 2022, attached is a copy of the presentation to be made at Glenmark Pharmaceuticals Limited Investor Day 2022 which is scheduled today at 17:30 IST, in Mumbai.Kindly take the same on record and acknowledge receipt.",
            "news_id": "df9ede70-3b86-428f-9d5e-166db0bd213d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8dce3da7-7f5a-4e96-b106-8970e4a0c8f1.pdf",
            "news_date": "2022-11-17 17:19:46",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio recording of Q2 of FY 2022-23 Earnings Call",
            "news_id": "3c11e6bd-7380-4140-a0e2-e54331422bd6",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8da8ba86-6d75-47ae-8b30-e7e1ac9499d9.pdf",
            "news_date": "2022-11-14 22:25:19",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) For The Second Quarter And Half Year Ended September 30, 2022",
            "news_body": "Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting approved the Unaudited Financial Results for the Second<BR> Quarter and Half Year ended September 30, 2022.<BR> The said meeting of the Board commenced at 2.00 p.m. and concluded at 6.20 p.m.<BR> The copy of the said results together with Management Discussion & Analysis, Press Release Investor Presentation and Limited Review Report of the Auditors is enclosed herewith.<BR> These are also being made available on the website of the Company at www.glenmarkpharma.com",
            "news_id": "19876e8d-b473-4cd7-b364-502801cef650",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c213bac9-eced-4c2f-99e2-de5c3260f970.pdf",
            "news_date": "2022-11-11 18:47:29",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Further to our letter dated 01st August, 2022 and pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, the transcript of the Earnings call held on Friday, August 12, 2022 for the quarter ended June 30, 2022 has been uploaded on the Company's website.",
            "news_id": "dd44a2a6-e4b3-43b2-bf2d-5179916ea2ef",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=23e6cd1c-b83c-46c6-bfae-d333481e2332.pdf",
            "news_date": "2022-08-17 11:01:20",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results Standalone And Consolidated For The First Quarter Ended June 30, 2022",
            "news_body": "Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting approved the Unaudited Financial Results for the First<BR> Quarter ended June 30, 2022.<BR> The said meeting of the Board commenced at 2.00 p.m. and concluded at 6.10 p.m. The copy of the said results together with Management Discussion & Analysis, Press Release<BR> Investor Presentation and Limited Review Report of the Auditors is enclosed herewith.<BR> These are also being made available on the website of the Company",
            "news_id": "f050a807-61c6-4ca8-8617-276b40b848ba",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0af2818f-d831-426b-9449-1abf28c25eb7.pdf",
            "news_date": "2022-08-10 18:39:26",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transactions For The Half Year Ended 31St March, 2022",
            "news_body": "Disclosure of Related Party Transactions for the half year ended 31st March, 2022",
            "news_id": "4bb9534c-3d9c-4670-86c1-732977cd05d6",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0de130e4-b62b-4e83-bf55-77ef01d0da27.pdf",
            "news_date": "2022-06-10 18:12:46",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Further to our letter dated 19th May, 2022 and pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015,the transcript of the Earnings call held on Monday, May 30, 2022 for the quarter and year ended March 31, 2022 has been uploaded on the Company's website.",
            "news_id": "a3de107e-4c70-4c61-a63f-1641be2f4cf1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c087f257-ede7-4807-8153-2594b1db9481.pdf",
            "news_date": "2022-06-03 17:37:20",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio recording of Q4 & FY22 Earnings Call",
            "news_id": "58734a68-1de5-4ad0-ab6a-4ef0d5fda426",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=45209f6f-4b2c-4972-81ea-7ddccb5c6a9e.pdf",
            "news_date": "2022-05-30 12:58:54",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results For The Year Ended March 31, 2022",
            "news_body": "Audited Financial Results for the year ended March 31, 2022. Pursuant to regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, find enclosed herewith the said results together with Management Discussion & Analysis, Press Release, Investor Presentation, Auditors Report and Declaration of unmodified opinion. These are also being made available on the website of the Company at www.glenmarkpharma.com<BR>",
            "news_id": "3587bd94-8ac0-4474-8695-dfc56bfc1d39",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9756ad4c-a893-4cdc-9315-5b43b500bbc4.pdf",
            "news_date": "2022-05-27 23:02:45",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) For The Third Quarter And Nine Months Ended December 31, 2021",
            "news_body": "Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting approved the Unaudited Financial Results for the                        Third Quarter and Nine Months ended December 31, 2021.<BR> <BR> The said meeting of the Board commenced at 5.30 p.m. and concluded at 10.15 p.m.<BR>  <BR> The copy of the said results together with Press Release, Management Discussion & Analysis, Investor Presentation and Limited Review Report of the Auditors is enclosed herewith.<BR>",
            "news_id": "aa419cd6-62bd-4a60-b819-75453a72a029",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=97854b39-1e67-449e-9644-c90583014762.pdf",
            "news_date": "2022-02-11 22:40:13",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) For The Second Quarter And Half Year Ended September 30, 2021",
            "news_body": "Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting approved the Unaudited Financial Results for the Second Quarter and Half Year ended September 30, 2021.<BR> <BR> The said meeting of the Board commenced at 5.30 p.m. and concluded at 9.40 p.m.<BR>  <BR> The copy of the said results together with Management Discussion & Analysis, Press Release, Investor Presentation and Limited Review Report of the Auditors is enclosed herewith.<BR> <BR> These are also being made available on the website of the Company at www.glenmarkpharma.com<BR> <BR> You are requested to take the same on record.<BR>",
            "news_id": "8082783b-d611-4d38-912e-6d58e0d9de31",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=72f9262f-5b86-4fab-8639-43767096f2fa.pdf",
            "news_date": "2021-11-12 22:08:27",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) For The First Quarter Ended June 30, 2021",
            "news_body": "Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting approved the Unaudited Financial Results for the First Quarter ended June 30, 2021.<BR> <BR> The said meeting of the Board commenced at 5.30 p.m. and concluded at 9.15 p.m.<BR>  <BR> The copy of the said results together with Management Discussion & Analysis, Press Release Investor Presentation and Limited Review Report of the Auditors is enclosed herewith.<BR> <BR> These are also being made available on the website of the Company at www.glenmarkpharma.com<BR>",
            "news_id": "5def1a71-ed3f-47ff-947c-6a70a3ec5d73",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=27fbba66-db64-4f74-b0f8-28eb4b453333.pdf",
            "news_date": "2021-08-13 21:42:22",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transactions Under Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015",
            "news_body": "Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the disclosure of Related Party Transactions on a consolidated basis drawn in accordance with the relevant accounting standards for the period ended 31st March, 2021.",
            "news_id": "2c32cc11-d09e-469f-bc6e-6983644b110f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c66fe3a9-4292-4808-bb00-b3b68d4a234d.pdf",
            "news_date": "2021-06-25 20:13:17",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results For The Year Ended March 31, 2021",
            "news_body": "Audited Financial Results for the year ended March 31, 2021. Pursuant to regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, find enclosed herewith the said results together with Management Discussion & Analysis, Press Release, Investor Presentation, Auditors Report and Declaration of unmodified opinion.<BR> Recommended Dividend @ 250% i.e. Rs. 2.50/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2020 - 21 subject to the approval of the Shareholders at the ensuing Annual General Meeting.",
            "news_id": "30d23a20-0f5e-4e05-ade1-2d6a802b288e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d2b03464-b23e-4e55-94a7-dc0a02aaabdf.pdf",
            "news_date": "2021-05-28 22:24:27",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) For The Third Quarter And Nine Months Ended December 31, 2020",
            "news_body": "Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting approved the Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2020.<BR> <BR> The said meeting of the Board commenced at 5.30 p.m. and concluded at 9.20 p.m.<BR>  <BR> The copy of the said results together with Management Discussion & Analysis, Press Release and Limited Review Report of the Auditors is enclosed herewith.<BR> <BR> These are also being made available on the website of the Company at www.glenmarkpharma.com",
            "news_id": "a6344939-49e9-4cc5-83d8-f3fba7e4ca9a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=55826d67-d9a0-4205-8a23-c4f47924ab52.pdf",
            "news_date": "2021-02-12 21:36:26",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        }
    ]
}